NCT07546448Not yet recruiting
Serum Electrolytes and Contrast-Induced Nephropathy in Acute Ischemic Stroke Patients Undergoing Endovascular Treatment
The Impact of Serum Electrolyte Levels on the Risk of Contrast-Induced Nephropathy in Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy
Source: ClinicalTrials.gov · Last updated 22 Apr 2026
Brief summary (registry, in English)
This study aims to evaluate the relationship between serum electrolyte levels and the development of contrast-induced acute kidney injury (CI-AKI) in patients with acute ischemic stroke undergoing endovascular therapy (EVT). Contrast-induced nephropathy remains a significant complication associated with endovascular procedures and is linked to increased morbidity and mortality. While several risk factors have been identified, the role of serum electrolyte imbalances in the development of CI-AKI has not been fully elucidated. In this retrospective cohort study, patients treated with EVT between 2018 and 2026 will be analyzed. Patients will be classified based on the presence or absence of CI-AKI according to changes in serum creatinine levels. Demographic data, comorbidities, laboratory parameters-including serum electrolytes-and procedural variables will be compared between groups. The primary objective is to determine whether serum electrolyte levels are associated with the risk of CI-AKI. Secondary objectives include evaluating 90-day mortality and dialysis dependency in patients who develop CI-AKI.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 250 (estimated)
- First submitted
- 2 Apr 2026
- Start date
- 20 Apr 2026
- Primary completion date
- 10 May 2026
- Lead sponsor
- Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital
- Diseases
- Stroke
- NCT number
- NCT07546448
What you commit to
- Study type: Observational
- Planned participants: 250
- From 20 Apr 2026 to the primary completion date, 10 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Exposure to iodinated contrast media within the previous 2 weeks
- Use of nephrotoxic medications within the previous 2 weeks
- History of myocardial infarction or previous stroke
- Systemic steroid use at the time of the procedure
Other illness
- Pre-existing acute kidney injury or chronic kidney disease meeting KDIGO stage 1-3 before endovascular therapy
- Known allergy or hypersensitivity to iodinated contrast media
Lab values
- Incomplete medical records or missing laboratory data required for evaluation of CI-AKI
Age
- Age younger than 18 years
Other
- APACHE score greater than 25 at the time of the procedure
- Use of vasopressor/inotropic agents such as dopamine at the time of the procedure
Who the study is looking for
- Adults aged 18 years or older
- Patients diagnosed with acute ischemic stroke
- Patients who underwent endovascular therapy for acute ischemic stroke between 2018 and 2026
- Patients with a baseline NIHSS score of 6 or higher
- Patients who received iodinated contrast medium during the endovascular procedure
- Patients managed under general anesthesia
- Patients with available pre-procedural and post-procedural serum creatinine measurements sufficient to assess contrast-induced acute kidney injury
Age in the registry: 18 years to 100 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fatma Acil Coordinator of this site? Confirm its status | Diyarbakır | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.